FAQ: CAR-T Therapy at BIOOCUS
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an advanced form of immunotherapy that uses genetically modified T-cells to target and kill cancer cells. It is used primarily for treating blood cancers like leukemia and lymphoma.
The CAR-T process typically takes about 6-8 weeks, from T-cell collection to infusion. The preparation phase, including the extraction and modification of T-cells, usually takes around 3-4 weeks.
CAR-T therapy is typically used for patients with specific types of blood cancers such as B-cell leukemia, lymphoma, and other hematologic malignancies. Eligibility is determined by factors such as previous treatments and the patient's overall health.
Common side effects include fever, chills, low blood pressure, and cytokine release syndrome (CRS), which can lead to severe immune reactions. Patients are closely monitored during treatment to manage these side effects.
You will need to undergo thorough testing to ensure you’re a suitable candidate. This includes blood tests, tumor imaging, and a review of your medical history. We will also coordinate your travel and hospital arrangements.
Yes, we encourage patients to bring a family member or friend for support during their stay. We provide assistance with accommodation and travel arrangements for your companion.
BIOOCUS provides comprehensive support for international patients, including visa assistance, flight recommendations, and accommodation arrangements. We will guide you through the process and ensure a smooth arrival.
While CAR-T therapy is often a one-time treatment, some patients may require additional infusions. We will discuss your situation and schedule follow-up treatments if needed.
After CAR-T therapy, you will need regular follow-up visits to monitor your health and the effectiveness of the treatment. These may include blood tests, imaging, and symptom tracking. Long-term monitoring is essential to ensure optimal outcomes.
While CAR-T therapy can offer durable remissions, there is always a risk of cancer recurrence. Continuous monitoring and follow-up care are essential to detect any signs of relapse early.
FAQ: TIL Therapy at BIOOCUS
TIL (Tumor-Infiltrating Lymphocyte) therapy is a form of immunotherapy where T-cells from the patient’s tumor are harvested, expanded in a lab, and then reinfused into the patient to attack cancer cells.
The TIL therapy process typically takes about 6-8 weeks. The initial step of tumor tissue collection and T-cell cultivation in the laboratory takes 3-4 weeks, followed by chemotherapy conditioning and TIL infusion.
TIL therapy is primarily used for solid tumors such as melanoma, lung cancer, cervical cancer, and some other advanced or metastatic cancers. Eligibility is based on tumor type and response to prior treatments.
Side effects of TIL therapy may include fatigue, fever, nausea, and cytokine release syndrome (CRS). As with CAR-T, the treatment is closely monitored to ensure patient safety.
Similar to CAR-T, preparation involves a comprehensive medical evaluation, including imaging, blood tests, and tumor biopsy. Once eligible, we will discuss the specifics of the procedure and coordinate logistics for your stay in China.
Yes, we encourage patients to bring a family member or friend for support during their stay. We provide assistance with accommodation and travel arrangements for your companion.
BIOOCUS provides comprehensive support for international patients, including visa assistance, flight recommendations, and accommodation arrangements. We will guide you through the process and ensure a smooth arrival.
The cost for TIL therapy at BIOOCUS typically ranges from $100,000 to $150,000 USD, depending on the complexity of the treatment and required follow-up care.
If TIL therapy proves to be beneficial, but cancer returns, additional infusions may be considered. We will monitor your progress and discuss any further treatment options after the initial infusion.
Following TIL therapy, patients will need regular check-ups to track cancer response and manage any long-term effects. This may include imaging, blood tests, and immune system monitoring.
While TIL therapy can offer durable remissions, there is always a risk of cancer recurrence. Continuous monitoring and follow-up care are essential to detect any signs of relapse early.